What Happens When You Stop a GLP-1

The short answer: when a GLP-1 medication is withdrawn, appetite signalling returns toward where it was before, and weight follows. In the STEP 1 trial extension, people who stopped semaglutide 2.4 mg regained about two-thirds of the weight they had lost within one year, and their improvements in blood pressure, blood sugar and lipids largely reverted with it. The SURMOUNT-4 trial found the same pattern with tirzepatide. This is the expected biology, not a character flaw — and it is the single most important thing to understand before starting, not after.

What the trials actually measured

Two withdrawal trials do most of the work here, and both are worth knowing by name because they are what your prescriber is thinking of.

STEP 1 extension (semaglutide 2.4 mg). Participants took the drug for 68 weeks, then everything stopped — drug and the trial's lifestyle programme. Mean weight loss at week 68 was 17.3%. One year later (week 120), the semaglutide group had regained 11.6 percentage points of body weight, leaving a net loss of 5.6% from where they started. The placebo group ended at 0.1%. Cardiometabolic markers moved back toward baseline in step with the weight: blood pressure rose in both groups, lipids and CRP climbed again after week 68, and of the semaglutide participants who had started with prediabetes and reached normal blood sugar on treatment, only about 43% were still there at week 120. The authors' own framing was that the findings confirm the chronicity of obesity and that ongoing treatment is needed to sustain the benefit.

SURMOUNT-4 (tirzepatide). After 36 weeks on a maximum tolerated dose of 10 or 15 mg, participants had lost a mean of 20.9% of body weight. They were then randomised to continue or to switch to placebo. Between week 36 and week 88, the placebo group regained 14.0% of body weight while the continuation group lost a further 5.5%. At week 88, 89.5% of those who kept taking tirzepatide had held on to at least 80% of their lead-in weight loss, versus 16.6% of those who stopped.

Two honest caveats that the headlines usually skip. First, average weight a year after stopping semaglutide was still below where people started — a mean net loss of 5.6%, which sits at the threshold at which cardiometabolic risk measurably improves. Regain is not a return to square one for the average participant, though the spread around that average was wide. Second, in STEP 1 the structured lifestyle support stopped at the same moment as the drug, so the extension measures "everything withdrawn at once", which is not identical to a planned change made with continued support.

Why regain happens — the mechanism, plainly

GLP-1 receptor agonists work while they are in your body. They amplify satiety signalling in the brain and gut, slow gastric emptying, and quiet the food-related mental chatter many people describe. None of that rewrites the body's set-point machinery. When the drug clears, the appetite signalling it was propping up returns to something like its previous level — and the body defends its old weight with the same tools it always used: more hunger, lower resting energy expenditure after weight loss, changed hormones such as ghrelin and leptin.

Obesity behaves like a chronic, relapsing condition. Nobody expects blood pressure to stay low after an antihypertensive is stopped; the medication was managing the condition, not curing it. GLP-1s are the same category of thing. The practical consequence is that these are best understood as long-term treatment for a chronic condition, not a course you finish — a genuinely important expectation to set before the first injection, because it changes how you plan for cost, coverage and side effects.

There is a body-composition wrinkle worth naming. During treatment, a meaningful share of the weight lost is lean mass, as it is with any substantial weight loss (see GLP-1s and muscle loss). Weight regained after stopping is generally thought to come back disproportionately as fat. Direct post-withdrawal body-composition data are thin, so we will not pretend to a precise figure — but the plausible outcome is that someone can return to a similar number on the scale with a less favourable ratio of muscle to fat than before. That is a strong reason to protect lean mass, and to be sceptical of anyone who tells you the scale is the only thing that matters.

The midlife-women angle

If you are in perimenopause or postmenopause, the deck is already stacked in a way that has nothing to do with willpower. Falling oestrogen shifts fat storage from hips and thighs toward the abdomen and visceral compartment, and age-related loss of muscle (sarcopenia) reduces resting energy expenditure. That is the same direction the body moves after a GLP-1 is withdrawn. So regain at midlife can arrive faster and land in a more metabolically unhelpful place — and it is a physiological headwind, not a moral event. Our guides to menopause weight gain and menopause belly fat go deeper on that biology.

Why people stop — none of it is shameful

Almost nobody stops a GLP-1 because they stopped caring. In real-world data, discontinuation within the first year is common, and the reasons cluster:

• Cost. The obvious one. Checked on the manufacturers' own pages on 13 July 2026: Novo Nordisk lists self-pay Wegovy through NovoCare Pharmacy at $349 per month for the 0.25, 0.5, 1, 1.7 and 2.4 mg doses, and $399 per month for the 7.2 mg HD dose. New patients starting on 0.25 mg or 0.5 mg are offered $199 per month, but only for the first two monthly fills, and only through 31 December 2026. Lilly lists Zepbound single-dose vials via LillyDirect at $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg) per month — with the $449 tier conditional on refilling within 45 days of the previous delivery. Miss that window and the higher doses jump to the standard self-pay price, listed as $599 at 7.5 mg rising to $1,049 at 15 mg. These are cash prices, they move, and they are not what you pay if you are insured. Check them yourself before you budget.
• Side effects. Nausea, vomiting, reflux and constipation are the usual culprits (see GLP-1 side effects).
• Coverage changes. A plan drops obesity-medication coverage at renewal, an employer changes carriers, prior authorisation lapses.
• Supply and product changes. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and set wind-down deadlines in early 2025 that ended the shortage-based route for mass compounding. Many people who had been using a compounded copy were pushed back toward branded pricing or off the drug entirely. Worth stating plainly: compounded GLP-1s are not FDA-approved. They are not reviewed by the FDA for safety, effectiveness, quality or potency, and the agency has documented real harm from the vial-and-syringe format they are usually sold in — people mixing up units on an insulin syringe with millilitres or milligrams and drawing five to twenty times the intended dose, with emergency-department visits as a result.
• Life. Pregnancy plans, surgery, a new diagnosis, a move.

One coverage change is genuinely new and worth checking if you are on Medicare: the Medicare GLP-1 Bridge, a time-limited CMS demonstration that began on 1 July 2026 and runs through 31 December 2027, offers eligible Part D beneficiaries certain GLP-1s approved for weight reduction at a $50 monthly cost share. Eligibility is not automatic — CMS applies clinical criteria based on BMI plus specified conditions, and the usual Part D rules are modified inside the demonstration. Verify your own eligibility on CMS.gov rather than taking a blog's word for it, including ours. You can also work through what your plan is likely to do with our cost and coverage estimator.

What may reduce the regain

The honest headline is that nothing yet reliably prevents regain after withdrawal. But some things are worth doing anyway, and the evidence for them is decent.

On dosing: what is written above is what the FDA-approved label publishes, and it is public fact. It is not an instruction. Your prescriber sets your dose. Do not self-adjust, taper, split, stretch or skip doses, and do not double up after a missed dose — the Wegovy label's own missed-dose rule is to skip the dose entirely if the next scheduled one is less than two days away, and dosing errors are a documented source of harm. If you want the label detail, our semaglutide drug page and GLP-1 dosing schedule lay it out as reference.

Talk to your prescriber — and what to ask

Nothing on this page is a reason to start or stop a medication. That decision is yours and your clinician's. Contact your prescriber promptly if you are considering stopping for any reason, and seek medical advice urgently for severe or persistent abdominal pain (possible pancreatitis or gallbladder disease), persistent vomiting or signs of dehydration, symptoms of low blood sugar if you also take insulin or a sulfonylurea, or a new lump in the neck, trouble swallowing or persistent hoarseness.

Bring these questions:

• If cost is my problem, is a lower maintenance dose clinically appropriate for me — and what would you expect to happen to my weight on it?
• What does my plan actually cover, and is there a prior-authorisation or step-therapy route we have not tried? (Ask for the plan's written criteria. Never misrepresent your situation to an insurer — it can void coverage and is fraud.)
• If I stop, what should we monitor, and how often — blood pressure, HbA1c, lipids?
• What is the realistic regain picture for someone like me, and at what point would we consider restarting?
• How do I protect muscle while this is happening? Who can help me build a resistance-training plan?

If you are weighing an online prescriber, judge it by whether a licensed clinician reviews your history, whether it dispenses FDA-approved product, whether it will coordinate with your own doctor, and how it handles you if you want to stop — not by its advertising. Disclosure: VidaBeacon may earn a commission from some links in our care-finder pages. That never determines what we say about the evidence, and we do not recommend any specific telehealth provider or pharmacy.

Related reading: how GLP-1 medications work, strength training for women, and our full weight and metabolism section.

This article is for information only and is not medical advice. Prices and coverage rules stated here were checked at the manufacturer and CMS pages on 13 July 2026 and change frequently; verify them at the source before relying on them.